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STU:)DIES of mechanisms by which estrogens and progestins play a role in
experimental carcinogenesis constitute an enormous literature, summarized in
part by Shimkin (1945), Dmochowski (1953), Muhlbock (1956), Gardner et al.
(1959), Noble (1964), lDao (1964), Cutts; Nandi; Jull (in Canadian (Cancer (!onf..
1966), and Russfield (1966). The concept prevalent in former decades, that estrogen
is a potent carcinogen and prime inducer of mammary cancer, has been tempered
by more recent findings which suggest that estrogens play a permissive, rather
thani a causative role (Bern. 1960), that they may act by way of the pituitary
(Kirschbaum. 1957; Boot et al., 1962), and that estrogen lacks effectiveness as an
inducer of mammary cancer in the mouse in the absence of mammary tumor
virus (Moore, 1963; Hall and Moore. 1966). As for the progestationcal moiety of
female sex hormones, progesterone was first reported to enhance acetylamino-
fluorene-induced mamtnnary carcinogenesis in the rat (Cantarow et al., 1948), and
subsequently was demonstrated also to enhanice mammary carcinogeniesis in rats
givein the polvcoclic carcinogens 3-methylcholanthrene or 9,10-dimethylbenz-
anthracenie (Huggins et al., 1959;3 Bonser et al.. 1961; Dao, 1964). More recently.
exogenous p)rogesteronie was showtn to enhance chemically-induced mammary
carcinogeniesis in mice, in the absence of demonstrable carcinogenic potency of
its owIn (Poel, 1965). The biologic effects of the hormone were described to be
typically co-carcinogenic (Poel. 1967). The present report confirms the observatiol
that progesterone, in viral and in chemically induced mammary carcinogenesis,
acts as a co-carcinogen; i.e., an agent lacking in carcinogenic potencv which
enhances the neoplastic response of a tissue to a carcinogen. The findings suggest
also a bioassay technique which exploits differences in spontaneous tumor sus-
ceptibilities of inbred strains of mice, to differentiate between co-carcinogenic and
carcinogenic potency. at least for progestins.
MATERIALS, METHODS, AND RESULTS
Tl'able I outlines one experiment to ascertain the effects of exogenous pro-
gesterone in intact C3HeB virgin female mice, a sub-line presumably free of
inammary tumor virus (MTV). Five groups of mice, initially 8 weeks of age.
were used. In 30 mice ofGroup 1, the effect ofprogesterone in enhancing chemical
carcinogeniesis was estimated by administering 2-5 mg progesterone in 0 05 ml.
peallut oil subcutaneously 5 times a week for 19 weeks, and 025 mg. methyl-
cholanthrene (MCA) in 0-1 ml. Tween 60, by gastric lavage (gavage), twice a week.
until a mammary tumor nodule was detected. Gavage feeding of MCA began 2
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TABLE I.-C3HeB Virgin Females (Free of Bittner MTV)
8 Weeks Old on Initial Exposure
Experimental life span (wks)
No. with with without
tumors TAT (wks) tumors tumors
Range Range Range
Exposure No. treatedf Median Median Median
1. 2 5mg. Proga+ . 2828 <18-23 22-28
0-25mg. 3-MCAb /219 25
2. 0-25 mg. 3-MCAb . 24/26 20->32 28-51 . 28, 66 28 40
3. 2-5 mg. ProgCd . 0/27 . . 2- >82*
4. Vehicles onlybcd . 0/28 30-82*3 57
5. Untreated controls . 0/24 . . 29-70*9
*68
weeks after administration of progesterone was initiated. For comparative
purposes, 30 mice of Group 2 were given MCA in Tween by gavage, and sub-
cutaneous injections of 0 05 ml. peanut oil instead of progesterone and peanut oil.
Group 3 received subcutaneous injections of progesterone in peanut oil 5 times a
week for 26 weeks and Tween by gavage twice a week, to ascertain whether the
hormone and solvents could elicit neoplastic reactions in the absence of MCA.
For comparative purposes, 30 mice in Group 4 received equivalent and concurrent
treatments with peanut oil and Tween. The fifth group of 24 mice provided a
comparative norm ofuntreated animals. Differences between the initial numbers
per group and those listed as " No. treated " in the table represent the few animals
lost because of cannibalism or excessive autolysis.
The data show a complete absence of mammary tumors in Groups 3, 4 and 5.
It is apparent from these 3 groups that progesterone was not a mammary car-
cinogen, that the solvent-vehicles employed were ineffective for inducing, or
enhancing the induction of mammary tumors, and that these animals either were
free of MTV, or the virus if present was incapable of inducing tumors under the
experimental conditions.
Mammary tumors in 24 of 26 survivors in Group 2 confirm the work of earlier
investigators, that MCA is a potent, systemically acting carcinogen for mammary
tumor induction. An even stronger carcinogenic reaction, indicative of pro-
gesterone-enhanced response to MCA is evidenced by Group 1. The development
of mammary tumors in all effectively exposed in Group 1, with a median tumor-
appearance time (TAT) of 19 weeks, and their death ofnatural causes by the 28th
week, in contrast with the data for Groups 2 and 3 (Table I), indicate that pro-
gesterone is a potent, non-carcinogenic co-carcinogen, for MCA-induced mammary
tumor development.
Table II presents data from a related experiment to ascertain the effects of
progesterone in C3H/He mice, a line presumed to harbor the Bittner MTV. A
principal objective in this study was to ascertain whether progesterone could
enhance viral carcinogenesis, latent in these animals, as well as the combination
of viral and chemically-induced mammary carcinogenesis theoretically possible
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TABLE II.-C3H Virgin Females (Harboring Bittner MTV)
10 Weeks Old on Initial Exposure
Experimental life span (wks)
No. with with without
tumors TAT (wks) tumors tumors
Range Range Range
Exposure No. treatedf Median Median Median
1. 2 5mg.Proga + 2 17-24 19-33
05mg. 3-MCAb 20 26
2. 0 5mg. 3-MCAb 90/21 32338
2943 26
2731 317896 3. 25 mg.Progad 21/249
27-73 31-77
55, 65, 67
45-78 52-78 50-78 4. 25 mg.Proge . 7/12 56 66 66
3. Vehicles only 6/24 730 52-72 64
6. Untreated controls 3/33 58, 58, 64 64, 70, 70 21- >8.*
a 2 5 mg. progesterone in 0 05 ml. peanut oil, subcutaneously 5 x a week for 19 weeks.
0 25 mg. or 0 5 mg. methylcholanthrene, as indicated, in 0 1 ml. Tween-60, by gavage 2
x a
week for a maximum of 35 weeks, or until a subcutaneous tumor was palpated. The animals were
given 005 ml. of peanut oil subcutaneously, 5 x a week, if they were not treated with progesterone
and methylcholanthrene concurrently. Gavage feedings of methylcholanthrene were begun 2 weeks
after treatment with progesterone was initiated.
C Treated 5 x a week for 26 weeks.
d These animals were also given 0-1 ml. Tween-60 by gavage, 2 x a week.
The 12 animals in this group were kept as vehicle controls until the 42nd week of the experiment,
at which time injections of progesterone were started and continued for the duration of their natural
life span.
f No. treated does not include animals that died during the first 10 weeks of the experiment, nor
those that died and were cannibalized or excessively autolyzed.
g Eight of the 24 mice received injections of progesterone from the 42nd week of the experiment
until the end of their natural life span, as well as during the first 19 weeks of the experiment. Six of
the 8 developed tumors before they died.
TAT Time of tumor appearance, in weeks.
*1 One survivor in group, free of mammary tumors, killed after 82nd week of experiment. *3 Three tumor-free survivors killed after 82nd week.
*9 Nine survivors killed because of pneumonitis.
*11 Eleven survivors free of tumors, killed to end experiment.
by feeding them MCA. The experimental plan is comparable to that seen in
Table I. Starting with virgin females, 10 weeks of age, 25 mice designated as
Group were treated with progesterone and MCA, utilizing the same dosage,
route, and frequency for administering progesterone as in the preceding experiment,
but feeding them 0-5 mg. MCA in 041 ml Tween 60, twice weekly by gavage
(cf. 0x25 mg. MCA in the preceding study), until a mammary tumor nodule was
detected. For comparison, 25 mice in Group 2 received 0-5 mg. MCA by gavage
concurrently with Group 1 but only peanut oil subcutaneously. To ascertain
the effect of progesterone on viral carcinogenesis due to intrinsic MTV, 25 mice in
Group 3 received progesterone in peanut oil subcutaneously, and Tween by gavage
during the first 19 weeks ofthe experiment. Eight tumor-free survivors of Group 3
after the 41st week of the experiment, were again given progesterone repeatedly.
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'T'o estimiiate the effect of exogenous progesterone wheni given only late in life,
12 mice that constitute Group 4 were kept as controls during the first 41 weeks,
and given progesterone thereafter. For comparison, 25 mice in Group 5 received
the vehicles peanut oil and Tween throughout the exposure period, while 33 mnice,
(lesignated as Group 6 were kept as untreated controls. As in the preceding
experiment, differences between the initial numbers of animals per groups and
those listed in the table represent losses due to cannibalism or excessive autolysis.
The uintreated controls of Group 6, Table II, yielded onlv 3 tumor-beariing
hiosts among the 33 mice. These tumors developing after the first year of life.
confirmyi observations of a decrease in the expected incidence of spontaneous
inammary tumors amonig some lines ofC3H mice currently available commercially.
'l'he relative increase in mamimary tumors among the vehicle-treated controls.
f'rom 3/33 in(Group 6 to 6/24 in Group 5) suggests that the test method in itself
can enhance an endogenousneoplastic agent or process in the test animal.
Groups39 aind 4 show obvious enhancement of endogenous viral carcinogenesis
associatedwith the administration of progesterone, as gauged by a significant rise
in mammary tumor incidence, and a decrease in time preceding tumor appearance
(TAT). The mammary tumors in 7 of the 12 mice in Group 4 began to develol)
3 weeks after administration of the hormone was started when the animals were
I year of age. A higher tumor incidence beginning at an earlier chronologic age is
evident in Group 3, where administration ofprogesteronie was begun at the age
of 10 weeks. There was significant difference in tumor frequency betweein the
mice in Group 3 treated with progesterone during the first 19 weeks of the experi-
ment only, as compared with the 8 treated during the first 19 weeks and again
from the 42nd week on, at which time they were still free of palpable tumors.
The data for(roup 2 (TableII) show a greater tumor frequency, ani earlier
1)eriod for tumor appearance, and a shorter experimental life span than are seen
in Groups 3-6. The toxicity of MCA, and its poteincy as amammaryeareiinogen
(Group 2) apparently exceed that of MTV plus progesterone (Groups 3 and 4)
under these experimental conditions. In Group I we see again thehighest tumor
inicidence, the shortest periods for tumor appearance, and shortest life spans.
related to the concurrent administration of MCA and progesterone.
The combined reactions of the 2 contrasting sub-lines of C33H mice thusitndicate
that progesterone under these experimental conditions is non-carcinogenic. but a
lhighly potent, target-specific co-carcinogeni, for the induction of mammary tumors
either with a viral agent, a systemically acting chemical carcinogen. or- botl
agents acting together.
DISCU SSION
The value of parallel experiments with inbred mice of differing sponltanleous tumuor propensities was seen in an earlier study, in which parallel exposures of'
initact C3H and C57 Leadenv.rgin female mice were made to 2 synthetic progestinl-
estrogen mixtures, used as oral contraceptives (Poel, 1966). A target-specific,
co-carcinogenic phenomenon was suggested by the development of pituitary
tumors in the C57L mice, a strain prone to pituitary tumor development. The
agents tested did not elicit a similar response in the C3H strain, in which sponta-
neous pituitary tumors have not been observed. The studies with synthetic and
niatural progestins thus suggest target specificity for progestins as co-carcinogens,
a phenomenon which is not seen in the biologic reaction to a topicallv active
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careinogen: both, studies also indicate the need for bioassays conducted with at
least 2 strains of mice that have contrasting spontaneous tumor characteristics.
Pertinent to the latter are the findings of Maisin and Coolen and other investi-
gators (reviewed by Shimkin; Dmochowski; Gardner; Jull; see below), that
cutaneous applications of MCA in some strains of mice induce mammary tumors.
By contrast, cutaneous applications of MCA on C57L mice induce skin malig- nancies rather than mammary tumors, and those are not influenced by concurrent
administration of progesterone. Because of differences in host reactivity and the lhistogenesis of the tumors, bioassays of progesterone for co-carcinogenic enhanlee- ment of skin carcinogenesis were negative with the C57L as the test strain, just as
tests for enhanced pituitary tumor development associated with the feeding of
svnthetic progestin mixtures were negative with C3H and C57/Black 6 mice (Poel. 1966 and 1967). Paired inbred strains, carefully selected because of dlifferenices in their tumor propensities. thus appear essential for long-term
bioassays, in lieu of just 1 strain of inbred test animal. Indirectly, these observa-
tions indicate also the need for parallel studies with random-bred mice, to enable t-he scientist to relate the highly refined reactions of the inbred animal to an
experimental model more akin to a population-at-large.
The reported findings confirm the preliminary observation (Poel, 1965) that
)rogesterone or the progestational state may provide " co-carcinogenic "enhance-
miient of viral, as well as chemically-induced mammary careinogenesis. The
term
"co-careinogen
" was introduced by Shear to designate a non-careinogenic
agent capable of promoting the host's neoplastic response to a carcinogen. As used by Greenstein (1954), co-careinogenesis designated the effect of a non-
carcinogenic agent which, in conjunction with a carcinogen administered at too
low a level to produce tumors, caused the production of such tuimors. That
specific usefulness of the term for designating agents that are not carcinogenic
perse, but enhance careinogenesis, has almost been lost for at least two reasons:
(a) The term originated and was used almost exclusively in studies of experi- menital skin carcinogenesis with crude mixtures (croton oil, creosote oil fractions).
or agents (urethane, viruses) that themselves were later found to be carcinogenic
(Clayson. 1966; Kawamoto et al., 1958; Poel, 1956: Roe, 1956; Salaman, 1958:
Salaman and Roe, 1964; Tannenbaum and Silverstone. 19,58; Tannenbaum, 1964:
VanDuuren, 1968). Most studies with crude croton oil or croton resin have been complicated by their non-carcinogenic, topically necrotizing components.
that distort thepatterns of carcinogenesis obtained with purified carcinogens.
Theisolation ofweakly carcinogenic phorbol esters that may be responsible for the
co-carcinogenic or carcinogenic effects of crude croton oil mixtures has beenl
reportied recently by Hecker (1966) and Van Duuren (19038). In the same vein.
however, the term has been used to designate additive or synergistic reactions
elicited by two or more agents known to be carcinogenic (Berenblum, 1968: (layson.1966: Salaman and Roe. 1964: Kawamoto et al.. 1958). a phenomenon
designated more recently by the term
" syncarcinogenesis
"
(b) The term has been applied to vehicles or solvents such asTweens anid
Spans (Setala, 1956: Della Porta et al.. 1960). whose solvency for a varietv of
carcinogens, penetration of tissue. and rates of diffusion or absorption exceed
those of distilled water. vegetable oils, toluene, or other solvents used in the early
days of experimental carcinogenesis. Extensive use of Tween-60 in control
animals, and as a solvent for topical anid systemically acting carcinogens in our'
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laboratory gave no evidence of carcinogenic or co-carcinogenic potency for this
vehicle (Poel, 1963). The existence of a class of co-carcinogens for the skin thus
remains a theoretical or speculative possibility requiring experimental validation.
Existence of the phenomenon of co-carcinogenesis, however, apparently may be
exemplified by enhancement of mammary carcinogenesis with progesterone, an
agent demonstrably negative in all tests to date for carcinogenic potency. In that
regard, the findings of Bern, Moore, and others may be interpreted to indicate the
need to re-investigate the role of other hormones, to ascertain whether they too
may not be acting as co-carcinogens, i.e., non-carcinogenic enhancers of target
tissues responding to environmental carcinogens.
SUMMARY
A carcinogenicity bioassay, based upon the differential responsiveness of two
inbred strains of mice with contrasting spontaneous tumor proclivities, showed
exogenous progesterone to be a potent co-carcinogen for viral or chemical induction
of mammary cancer in mice, although non-carcinogenic by itself. The findings
emphasize the need to limit the term " co-carcinogen " to non-carcinogenic co-
factors, other than solvents, which enhance the neoplastic responsiveness of a
host's tissue to a carcinogen.
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